Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: Subgroup analyses of the phase 3 POLLUX study

Kenshi Suzuki, Meletios A. Dimopoulos, Naoki Takezako, Shinichiro Okamoto, Atsushi Shinagawa, Morio Matsumoto, Hiroshi Kosugi, Sung Soo Yoon, Shang Yi Huang, Xiang Qin, Ming Qi, Shinsuke Iida

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

In the phase 3 POLLUX study, daratumumab plus lenalidomide and dexamethasone (DRd) significantly reduced the risk of progression/death and induced deeper responses vs. lenalidomide and dexamethasone alone (Rd) in patients with relapsed/refractory multiple myeloma (RRMM). We report a subgroup analysis of East Asian (Japanese, Korean, and Taiwanese) patients from POLLUX based on a longer follow-up of 24.7 months. Median progression-free survival was not reached (NR) for DRd vs. 13.8 months for Rd (hazard ratio [HR], 0.42; 95% confidence interval [CI], 0.23-0.76), and overall response rates were higher for DRd vs. Rd (90.2 vs. 72.1%). DRd extended the median duration of response vs. Rd (NR vs. 20.2 months), and minimal residual disease-negative rates at the 10-5 sensitivity threshold were 21.2 vs. 9.1% for DRd vs. Rd. No new safety signals were observed. Similar efficacy and safety were observed in the smaller subgroup of Japanese patients treated with DRd vs. Rd. These results demonstrate favorable efficacy and safety of DRd vs. Rd in East Asian patients and also in the Japanese-only patient subgroup that are consistent with findings in the overall patient population of POLLUX.

Original languageEnglish
Article number41
JournalBlood Cancer Journal
Volume8
Issue number4
DOIs
Publication statusPublished - 2018 Apr 1

    Fingerprint

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Suzuki, K., Dimopoulos, M. A., Takezako, N., Okamoto, S., Shinagawa, A., Matsumoto, M., Kosugi, H., Yoon, S. S., Huang, S. Y., Qin, X., Qi, M., & Iida, S. (2018). Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: Subgroup analyses of the phase 3 POLLUX study. Blood Cancer Journal, 8(4), [41]. https://doi.org/10.1038/s41408-018-0071-x